Cargando…
Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials
BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a generally safe and well tolerated antidiabetic drug class with proven efficacy in type 2 diabetes mellitus (T2DM). Recently, a series of large, randomized controlled trials (RCTs) addressing cardiovascular outcomes with DPP-4 inhibitors hav...
Autores principales: | Patoulias, Dimitrios Ioannis, Boulmpou, Aristi, Teperikidis, Eleftherios, Katsimardou, Alexandra, Siskos, Fotios, Doumas, Michael, Papadopoulos, Christodoulos E, Vassilikos, Vassilios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554356/ https://www.ncbi.nlm.nih.gov/pubmed/34754403 http://dx.doi.org/10.4330/wjc.v13.i10.585 |
Ejemplares similares
-
Colchicine as a Potential Therapeutic Agent Against Cardiovascular Complications of COVID-19: an Exploratory Review
por: Papadopoulos, Christodoulos, et al.
Publicado: (2020) -
The Impact of Metabolic Syndrome Components on Erectile Function in Patients with Type 2 Diabetes
por: Katsimardou, Alexandra, et al.
Publicado: (2023) -
Glucagon-like Peptide-1 Receptor Agonists and the Risk of Acute Kidney Injury: Alarming, or Not?
por: Patoulias, Dimitrios, et al.
Publicado: (2021) -
Homocysteine as a Predictor of Paroxysmal Atrial Fibrillation-Related Events: A Scoping Review of the Literature
por: Charalampidis, Panagiotis, et al.
Publicado: (2022) -
Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus
por: Patoulias, Dimitrios, et al.
Publicado: (2022)